RxDoctor Payments Data

Nitin Relia, MD

Nephrology · Vineland, NJNPI 1952531857

Payments from drug & device makers

$3,780in general payments, 2019–2025

Across 183 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$705
  • Otsuka America Pharmaceutical, Inc.$519
  • Bayer$243
  • Ardelyx, Inc.$232
  • OPKO Pharmaceuticals, LLC$228
  • Akebia Therapeutics Inc$204
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$3,62496%
  • Education$1574%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,780 in reported general payments places this provider in the 75th percentile of 413 nephrology providers in New Jersey.

See all nephrology providers in New Jersey

Medicare billing

Part B allowed, 2024
$373,645
Medicare patients
546
Services billed
3,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol50$66,614
JardianceEmpagliflozin14$24,035
RayaldeeCalcifediol13$16,795
Sevelamer Carbonate15$4,816
Cinacalcet Hcl14$3,256
Nifedipine ErNifedipine53$2,537
Bumetanide74$2,435
Valsartan64$1,893
Allopurinol86$928
Tamsulosin Hcl26$785
Hydralazine Hcl32$735
Amlodipine Besylate75$716
Carvedilol54$538
Furosemide126$535
Losartan Potassium22$437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$705$66,61450 claims
Boehringer IngelheimJardiance$115$24,03514 claims
OPKO Pharmaceuticals, LLCRayaldee$228$16,79513 claims
ANI Pharmaceuticals, Inc.Valsartan$146$1,89364 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 413 nephrology providers in New Jersey.

Other nephrology in Vineland

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →